Recent headlines reveal a troubling trend: missed endpoints, inconsistent results, and major failures in Alzheimer’s Disease (AD) clinical trials. Inadequate cognitive scales are cited as a key reason behind the 98% failure rate in Phase II and III trials.
Take Lecanemab as an example—approved in the UK but deemed insufficient for NHS use due to limited cognitive benefits. According to John Harrison of Alzheimer Center Amsterdam, broader assessment methods could have altered the outcome.
Join our community of smart and fun people from across the world who generously share their ideas, learnings, and resources with each other. We’ll also, send a short summary directly to your inbox never more than once a week.
© 2025 Marketboats Consulting, Inc. All Rights Reserved.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to our use of all cookies, however, you may visit “Cookies Setting” to provide a controlled consent.